These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 28967920)

  • 1. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
    Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
    Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1.
    Romero R; Sánchez-Rivera FJ; Westcott PMK; Mercer KL; Bhutkar A; Muir A; González Robles TJ; Lamboy Rodríguez S; Liao LZ; Ng SR; Li L; Colón CI; Naranjo S; Beytagh MC; Lewis CA; Hsu PP; Bronson RT; Vander Heiden MG; Jacks T
    Nat Cancer; 2020 Jun; 1(6):589-602. PubMed ID: 34414377
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
    EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
    Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
    Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
    Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MM; Janne PA; Van Allen EM; Barbie DA; Vokes NI
    Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
    Riess JW; Frankel P; Shackelford D; Dunphy M; Badawi RD; Nardo L; Cherry SR; Lanza I; Reid J; Gonsalves WI; Kunos C; Gandara DR; Lara PN; Newman E; Paik PK
    Clin Lung Cancer; 2021 Jan; 22(1):67-70. PubMed ID: 33229301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
    Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
    Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
    Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote
    Xu J; Guo H; Xing Z; Zhang W; He J; Cheng J; Cai R
    Oxid Med Cell Longev; 2020; 2020():6240125. PubMed ID: 33299528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
    Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
    Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.
    Hamada S; Matsumoto R; Tanaka Y; Taguchi K; Yamamoto M; Masamune A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
    Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
    Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
    Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
    Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
    Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.